Disposition kinetics of dihydroquinidine following quinidine administration
- PMID: 940955
Disposition kinetics of dihydroquinidine following quinidine administration
Abstract
The disposition kinetics of dihydroquinidine, a known impurity in drug grade quinidine, was studied in 7 patients who were hospitalized for control of cardiac arrhythmias. Quinidine gluconate injection containing 5.4 to 6.2 percent dihydroquinidine was used. Following an overnite fast, dihydroquinidine doses of 0.16 to 0.31 mg/kg base were infused intravenously over 22 min. Plasma samples were collected at various times for 12 hr and analyzed for dihydroquinidine by a thin layer chromatography-fluorometric assay procedure. Postinfusion plasma dihydroquinidine concentration decline was described by a biexponential equation which suggested that the impurity distributes within the body in two kinetically distinguishable pools. The volume of the central pool (Vc) and steady-state volume of distribution (Vdss) were 0.67 +/- 0.15 L/kg and 2.76 +/- 0.63 L/kg, respectively. The halflife of the fast (t1/2alpha) and slow (t1/2beta) disposition processes were 4.71 +/- 0.26 min and 5.71 +/- 1.00 hr. Total plasma clearance was 4.17 +/- 0.68 ml/min/kg. Renal excretion of intact dihydroquinidine accounted for 16 percent of the administered dose. The corresponding value for renal dihydroquinidine clearance (Clr) was 0.61 +/- 0.08 ml/min/kg. The results of this study indicated that there were no significant differences in the distribution and elimination characteristics of dihydroquinidine and quinidine.
Similar articles
-
Clinical pharmacokinetics of quinidine.Clin Pharmacokinet. 1980 Mar-Apr;5(2):150-68. doi: 10.2165/00003088-198005020-00003. Clin Pharmacokinet. 1980. PMID: 6988137 Review.
-
The bioavailability and kinetics of dihydroquinidine in patients with heart disease.Int J Clin Pharmacol Ther Toxicol. 1982 May;20(5):212-8. Int J Clin Pharmacol Ther Toxicol. 1982. PMID: 7095920
-
Disposition kinetics of quinidine.Clin Pharmacol Ther. 1976 Jan;19(1):30-6. doi: 10.1002/cpt197619130. Clin Pharmacol Ther. 1976. PMID: 1245091
-
Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration.Eur J Clin Pharmacol. 1979 Sep;16(2):101-5. doi: 10.1007/BF00563115. Eur J Clin Pharmacol. 1979. PMID: 499305
-
The clinical usefulness of the antiarrhythmic drug quinidine.Eur Heart J. 1987 Mar;8 Suppl A:1-9. doi: 10.1093/eurheartj/8.suppl_a.1. Eur Heart J. 1987. PMID: 3556171 Review. No abstract available.
Cited by
-
Absorption of quinidine and dihydroquinidine in humans.Eur J Clin Pharmacol. 1981;21(3):195-9. doi: 10.1007/BF00627920. Eur J Clin Pharmacol. 1981. PMID: 7318878
-
Clinical pharmacokinetics of quinidine.Clin Pharmacokinet. 1980 Mar-Apr;5(2):150-68. doi: 10.2165/00003088-198005020-00003. Clin Pharmacokinet. 1980. PMID: 6988137 Review.
-
Therapeutic drug monitoring of antiarrhythmic agents.Clin Pharmacokinet. 1982 Mar-Apr;7(2):125-48. doi: 10.2165/00003088-198207020-00003. Clin Pharmacokinet. 1982. PMID: 7039925 Review. No abstract available.
-
Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.Eur J Drug Metab Pharmacokinet. 1986 Jul-Sep;11(3):233-8. doi: 10.1007/BF03189851. Eur J Drug Metab Pharmacokinet. 1986. PMID: 3816879 Clinical Trial.
-
Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration.Cardiovasc Drugs Ther. 1988 Dec;2(5):679-86. doi: 10.1007/BF00054209. Cardiovasc Drugs Ther. 1988. PMID: 2484920 Clinical Trial.